Statement: At least one type of respiratory illness was observed in patients from both the primary trial and the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 7/39 (17.95%)   Gastroenteritis viral 1/39 (2.56%)   Parainfluenzae virus infection 1/39 (2.56%)   Seizure 4/39 (10.26%)   Headache 1/39 (2.56%)   Hydrocephalus 1/39 (2.56%)   Hypertension 1/39 (2.56%)
Secondary_evidence: Adverse Events 1:   Total: 20/70 (28.57%)   NAUSEA 2/70 (2.86%)   VOMITING 1/70 (1.43%)   DIARRHOEA 2/70 (2.86%)   ABDOMINAL PAIN 1/70 (1.43%)   ABDOMINAL PAIN LOWER 1/70 (1.43%)   FATIGUE 2/70 (2.86%)   PYREXIA 1/70 (1.43%)   OEDEMA PERIPHERAL 1/70 (1.43%)   GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%)   PNEUMONIA 1/70 (1.43%)   SINUSITIS 1/70 (1.43%)   LOBAR PNEUMONIA 1/70 (1.43%) Adverse Events 2: